Abstract
Many difficult-to-treat clinical entities in the cardiovascular field are characterized by pronounced sympathetic overactivity, including resistant hypertension and heart failure, underlining the need to explore therapeutic options beyond pharmacotherapy. Autonomic modulation via carotid baroreceptor activation has already been evaluated in clinical trials for resistant hypertension, and relevant outcomes with regard to safety and efficacy of the technique are critically presented. The pathophysiological background of heart failure renders carotid baroreceptor stimulation a potential treatment candidate for the disease. Available data from animal models with heart failure point towards significant cardioprotective benefits of this innovative technique. Accordingly, the effects of baroreceptor activation treatment (BAT) on cardiac parameters of hypertensive patients are well-promising, setting the basis for upcoming clinical trials with baroreflex activation on patients with heart failure. However, as the potential therapeutic of BAT unfolds and new perspectives are highlighted, several concerns are raised that should be meticulously addressed before the wide application of this invasive procedure is set in the limelight.
Keywords: Carotid baroreceptor stimulation, baroreflex, hypertension, heart failure, resistant hypertension, heart failure with preserved ejection fraction, sympathetic nervous system.
Current Vascular Pharmacology
Title:Carotid Baroreceptor Stimulation: A Promising Approach for the Management of Resistant Hypertension and Heart Failure
Volume: 12 Issue: 1
Author(s): Doumas M., Faselis C., Kokkinos P., Anyfanti P., Tsioufis C. and Papademetriou V.
Affiliation:
Keywords: Carotid baroreceptor stimulation, baroreflex, hypertension, heart failure, resistant hypertension, heart failure with preserved ejection fraction, sympathetic nervous system.
Abstract: Many difficult-to-treat clinical entities in the cardiovascular field are characterized by pronounced sympathetic overactivity, including resistant hypertension and heart failure, underlining the need to explore therapeutic options beyond pharmacotherapy. Autonomic modulation via carotid baroreceptor activation has already been evaluated in clinical trials for resistant hypertension, and relevant outcomes with regard to safety and efficacy of the technique are critically presented. The pathophysiological background of heart failure renders carotid baroreceptor stimulation a potential treatment candidate for the disease. Available data from animal models with heart failure point towards significant cardioprotective benefits of this innovative technique. Accordingly, the effects of baroreceptor activation treatment (BAT) on cardiac parameters of hypertensive patients are well-promising, setting the basis for upcoming clinical trials with baroreflex activation on patients with heart failure. However, as the potential therapeutic of BAT unfolds and new perspectives are highlighted, several concerns are raised that should be meticulously addressed before the wide application of this invasive procedure is set in the limelight.
Export Options
About this article
Cite this article as:
M. Doumas, C. Faselis, P. Kokkinos, P. Anyfanti, C. Tsioufis and V. Papademetriou, Carotid Baroreceptor Stimulation: A Promising Approach for the Management of Resistant Hypertension and Heart Failure, Current Vascular Pharmacology 2014; 12 (1) . https://dx.doi.org/10.2174/15701611113119990138
DOI https://dx.doi.org/10.2174/15701611113119990138 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Functional, Genetic and Biochemical Biomarkers of Peripheral Arterial Disease
Current Medicinal Chemistry Neuroprotection by Alpha 2-Adrenergic Agonists in Cerebral Ischemia
Current Neuropharmacology Tackling Cardiovascular Risk: New Evidence from Personalized Medicine
Current Pharmacogenomics and Personalized Medicine Emerging Role of Complement in Ocular Diseases
Current Immunology Reviews (Discontinued) Renal Artery Stenting: Efficacy and Complications
Current Hypertension Reviews Cyclic Nucleotide Phosphodiesterases (PDE) and Peptide Motifs
Current Pharmaceutical Design Cardiotonic Steroids: Novel Mechanisms of Na+ i-Mediated and - Independent Signaling Involved in the Regulation of Gene Expression, Proliferation and Cell Death
Current Hypertension Reviews Taurine Analogues; A New Class of Therapeutics: Retrospect and Prospects
Current Medicinal Chemistry Pharmacokinetic Study of Amlodipine in Human Urine Using On-Line Coupled Isotachophoresis-Capillary Zone Electrophoresis with Diode Array Detection
Current Pharmaceutical Analysis Copeptin in Preeclampsia Development
Current Women`s Health Reviews Advanced Therapies For End-Stage Heart Failure
Current Cardiology Reviews Insulin Resistance in the HIV-Infected Population: The Potential Role of Mitochondrial Dysfunction
Current Drug Targets - Infectious Disorders Why Not All Hypertensive Patients Are Tachycardic at Rest?
Current Pharmaceutical Design Molecular Concept of Diabetic Wound Healing: Effective Role of Herbal Remedies
Mini-Reviews in Medicinal Chemistry Detection of a Left Atrial Thrombus Under Fondaparinux Treatment: A Case Report
Current Drug Safety Editorial: MicroRNA-33 Inhibition: A Potential Adjunct to Statin Therapy?
Current Vascular Pharmacology Therapeutic Targeting of Endothelial Dysfunction in Chronic Diabetic Complications
Recent Patents on Cardiovascular Drug Discovery Vandetanib, A Dual Inhibitor of VEGFR and EGFR Tyrosine Kinase Activity
Current Cancer Therapy Reviews Blockade of the Renin-Angiotensin-Aldosterone System: Effects on Hypertensive Target Organ Damage
Cardiovascular & Hematological Agents in Medicinal Chemistry Anti-VEGF Treatment in Corneal Diseases
Current Drug Targets